Bio-Techne company profile
Company profile
Bio-Techne has 3,000 employees and is headquartered in Minneapolis, United States.
Based in Minneapolis, Minnesota, Bio-Techne has existed since its incorporation in 1976. Its portfolio centers on biological reagents such as cytokines, growth factors and antibodies, supplied to research laboratories, clinical diagnostics makers and developers of cell and gene therapies. It also offers diagnostic controls, calibrators and assays, tissue-based spatial analysis kits, and instruments and control products for hematology and blood chemistry. Known as Techne Corporation until November 2014, it serves customers across many countries.
In the fiscal year ended June 2026, revenue was $1.2 billion, down 0.4% from the previous year, and net income was $181.9 million. The United States accounted for 52.3% of revenue, followed by Europe, the Middle East and Africa excluding the UK at 24.2% and China at 8.6%. The company had 3,000 employees.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Headquarters
- 614 McKinley Place N.E., 55413, Minneapolis
- Employees
- 3,000
- Chief executive
- Kim Kelderman
- Founded
- 1976
- Fiscal year
- July - June
- Listing
- TECH · NASDAQ
- Indices
- S&P 500
- Currency
- USD
- ISIN
- US09073M1045
- Website
- bio-techne.com
Bio-Techne and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Bio-TechneTECH | United States | $11.43B | 3,000 | 21.7% | 66.8 |
| Summit TherapeuticsSMMT | United States | $11.32B | 265 | 0.0% | — |
| BioMarin PharmaceuticalBMRN | United States | $11.09B | 3,221 | 16.3% | 146.8 |
| Madrigal PharmaceuticalsMDGL | United States | $9.93B | 915 | -10.7% | — |
| Corcept TherapeuticsCORT | United States | $9.36B | 730 | 0.8% | 190.2 |
| Halozyme TherapeuticsHALO | United States | $14.67B | 423 | 56.8% | 38.3 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
